Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 6, 2010, Pages 634-636

  Bedi, Gurdesh ^a   Brown, Andrew ^a   Tong, Tao ^a   Sharma, Khema R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ASSESSMENT; DRUG DOSE TITRATION; DRUG EFFICACY; ELECTROPHYSIOLOGY; FEMALE; HUMAN; LABORATORY TEST; MALE; MEDICAL RECORD REVIEW; NEUROPATHY IMPAIRMENT SCORE; PRIORITY JOURNAL; RATING SCALE; TREATMENT DURATION;

EID: 77953712395     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.177576     Document Type: Article

References (25)

1. McLeod JG, Pollard JD,Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999;46:910-13.
2. Quattrini A, Previtali SC, Kieseier BC, et al. Autoimmunity in the peripheral nervous system. Crit Rev Neurobiol 2003;15:1-39.
3. Melendez-Vazquez C, Redford J, Chaudhary PP, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuro Immunol 1997;73:124-34.
4. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
5. Dyck PJ, O'Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985;35:1173-6. (Pubitemid 15003451)
6. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-9.
7. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-45.
8. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-66. (Pubitemid 26300708)
9. Hadden RD, Sharrack B, Bensa S, et al. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53:57-61. (Pubitemid 29329649)
10. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2003;1:CD003280.
11. Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-6. (Pubitemid 32059658)
12. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-22.
13. Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2002;9:683-5.
14. Benedetti L, Grandis M, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004;29:748-9.
15. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004;63:715-17.
16. Radziwill AJ, Schweikert K, Kuntzer T, et al. Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy - an open-label study. Eur Neurol 2006;56:37-8.
17. Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-24.
18. Sharma KR, Cross J, Farronay O, et al. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002;59:758-65.
19. Dyck PJ, Litchy WJ, Lehman K, et al. Variables influencing neuropathic end points: The Rochester diabetic neuropathy study of healthy subjects. Neurology 1995;45:1115-21.
20. Sharma KR, Cross J, Ayyar DR, et al. Diabetic demyelinating polyneuropathy responsive to immunoglobulin therapy. Arch Neurol 2002;59:751-7. (Pubitemid 34517756)
21. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanism of action. Immunopharmacology 2000;47:85-118.
22. Hood KA, Zarimbski DG. Mycophenolate mofetil: A unique immunosuppressive agent. Am J Health Syst Pharm 1997;54:285-94.
23. Piepers S, Van den Berg-Vos R, Van der Pol W, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: randomized, controlled trial. Brain 2007;130:2004-10.
24. Pisoni CN, Caudrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology 2007;46:516-18.
25. Hehir M, Burns T, Alpers J, et al. Long-term experience with mycophenolate mofetil (MMF) in myasthenia gravis (MG):retrospective analysis of 103 patients. Neurology 2009;72(suppl 3):A440 (abstract).